Capricor initiates rolling BLA submission to FDA for deramiocel in DMD cardiomyopathy

CAPRICOR THERAPEUTICS, INC.

Rolling submission started Oct 9, 2024; plans to complete by end of 2024.
BLA seeks full approval for deramiocel to treat all DMD cardiomyopathy patients.
No approved treatments currently exist for DMD cardiomyopathy.
Application may be eligible for priority review by FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.